Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3016 to 3030 of 7690 results

  1. Immunisation: DTaP (8 months) (IND215)

    This indicator covers the percentage of babies who reached 8 months old in the preceding 12 months, who have received at least 3 doses of a diphtheria, tetanus and pertussis containing vaccine before the age of 8 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM197

  2. Asthma: annual review (IND188)

    This indicator covers the percentage of patients with asthma on the register, who have had an asthma review in the preceding 12 months that includes an assessment of asthma control using a validated asthma control questionnaire (including assessment of short acting beta agonist use), a recording of the number of exacerbations and a written personalised action plan. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM167

  3. Diabetes: statins for secondary prevention of CVD (IND184)

    This indicator covers the percentage of patients with diabetes and a history of cardiovascular disease (excluding a history of haemorrhagic stroke) who are currently treated with a statin. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM163

  4. Pregnancy and neonates: postnatal mental health (IND178)

    This indicator covers the percentage of women who have given birth in the preceding 12 months who have had an enquiry about their mental health between 4 to 16 weeks postpartum. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM156

  5. Screening: cervical screening (50 to 64 years) (IND177)

    This indicator covers the proportion of patients eligible for cervical screening and aged 50 to 64 years at end of period reported whose notes record that an adequate cervical screening test has been performed in the previous 5.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM155

  6. Screening: cervical screening (25 to 49 years) (IND176)

    This indicator covers the proportion of patients eligible for cervical screening and aged 25 to 49 years at end of period reported whose notes record that an adequate cervical screening test has been performed in the previous 3.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM154

  7. Interventional procedures advisory committee members

    Interventional Procedures Advisory Committee members

  8. Audit and service improvement

    Resources to help with planning ahead for NICE guidance, understanding where you are now, and conducting improvement initiatives.

  9. NICE committees

    Develop our recommendations on a NICE committee as a chair, professional member or person with lived experience.

  10. Baseline assessment tools

    Our baseline assessment, audit, costing and service planning tools can now be found in the guidance section of our website , on the tools and...

  11. Audit tools

    Our baseline assessment, audit, costing and service planning tools can now be found in the guidance section of our website , on the tools and...

  12. Resource impact reports and templates

    Our baseline assessment, audit, costing and service planning tools can now be found in the guidance section of our website , on the tools and...

  13. Service planning

    Our baseline assessment, audit, costing and service planning tools can now be found in the guidance section of our website , on the tools and...

  14. Board

    Our board sets out our strategic priorities and policies.

  15. UK licensing and technology appraisals

    What we do NICE has a key role in the evaluation of and access to new and innovative medicines and treatments for the health system, playing an...